CAST
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis
Trial ID
ACTRN12618000505202
Cancer type
Acute leukaemia and myelodysplasia (MDS)
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Brief summary
A clinical trial to test if the treatment combination cyclosporin and post-transplant cyclophosphamide is better than the standard treatment given for acute leukaemia and myelodysplasia cancer to prevent graft-versus-host disease (GVHD).
The treating doctor has recommended allogeneic stem cell transplant, where stem cells given use the donor’s (sibling) immune system to destroy cancer cells. A complication of allogeneic stem cell transplant is GVHD, where the donor’s immune cells do not recognise the recipient’s body as foreign and attack the body (similar to when the immune system fights a virus / infection). The standard treatment given to prevent GVHD is the combination of cyclosporin and methotrexate (chemotherapy treatment) given following transplant. Cyclosporin is taken orally and cyclophosphamide is given as an infusion into the vein.
Patients will be randomly selected to receive one of the following treatment combinations:
Arm A: Cyclosporin and post-transplant cyclophosphamide
Arm B: Post-transplant cyclosporin and methotrexate
Who can participate
- Are between 18 and 70 years old
- Have acute leukaemia and myelodysplasia
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.